Ex vivo CRISPR gene editing in hematopoietic stem and progenitor cells has opened potential treatment modalities for numerous diseases. The current process uses electroporation, sometimes followed by virus transduction. While this complex manipulation has resulted in high levels of gene editing at some genetic loci, cellular toxicity was observed. We have developed a CRISPR nanoformulation based on colloidal gold nanoparticles with a unique loading design capable of cellular entry without the need for electroporation or viruses. This highly monodispersed nanoformulation avoids lysosomal entrapment and localizes to the nucleus in primary human blood progenitors without toxicity. Nanoformulation-mediated gene editing is efficient and sustained with different CRISPR nucleases at multiple loci of therapeutic interest. Engraftment kinetics of nanoformulation-treated primary cells in humanized mice are better relative to nontreated cells, with no differences in differentiation. Here we demonstrate nontoxic delivery of the entire CRISPR payload into primary human blood progenitors. Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:
A hallmark of Fanconi anemia is accelerated decline in hematopoietic stem and
progenitor cells (CD34 +) leading to bone marrow failure. Long-term treatment
requires hematopoietic cell transplantation from an unaffected donor but is
associated with potentially severe side-effects. Gene therapy to correct the
genetic defect in the patient’s own CD34+ cells has been
limited by low CD34+ cell numbers and viability. Here we demonstrate
an altered ratio of CD34Hi to CD34Lo cells in Fanconi
patients relative to healthy donors, with exclusive in vitro
repopulating ability in only CD34Hi cells, underscoring a need for
novel strategies to preserve limited CD34+ cells. To address this
need, we developed a clinical protocol to deplete
lineage+(CD3+, CD14+, CD16+ and
CD19+) cells from blood and marrow products. This process
depletes >90% of lineage+cells while retaining
≥60% of the initial CD34+cell fraction, reduces total
nucleated cells by 1–2 logs, and maintains transduction efficiency and
cell viability following gene transfer. Importantly, transduced
lineage− cell products engrafted equivalently to that of
purified CD34+ cells from the same donor when xenotransplanted at
matched CD34+ cell doses. This novel selection strategy has been
approved by the regulatory agencies in a gene therapy study for Fanconi anemia
patients (NCI Clinical Trial Reporting Program Registry ID
NCI-2011-00202; clinicaltrials.gov identifier:
01331018).
Key Points
The cyclic resveratrol trimer caraphenol A safely enhances lentiviral vector gene delivery to hematopoietic stem and progenitor cells. Caraphenol A decreases interferon-induced transmembrane protein-mediated restriction in an endosomal trafficking-dependent manner.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.